4th Apr 2016 08:33
LONDON (Alliance News) - Onzima Ventures PLC said Monday that N4 Pharma Ltd, in which Onzima has a 49% stake, has acquired from the University of Queensland exclusive global rights to commercialise a nano-particle vaccine delivery system for messenger RNA particles.
N4 already has similar agreements in place with the University of Queensland, under which it has the rights to commercialise a nano-particle vaccine delivery system for plasmid DNA and certain subunit vaccines, but the agreement announced on Monday extends the relationship to include messenger RNA particles.
Under the deal, N4 will undertake further research and experimentation with the university to develop a strong in-vitro data package, looking at the high protective loading capacity of plasmid DNA and messenger RNA and demonstrating their strong transfection capability
"Over the next few months we will continue to undertake experiments to demonstrate the capability of our vectors for both plasmid DNA and messenger RNA, publishing the data when we can with a view to looking to engage with potential partners in the second half of 2016 to either work with their own particles or potentially acquire the rights to particles ourselves which we can then seek to take forward using these vectors," said N4 Chief Executive Officer Nigel Theobald in a statement.
Shares in Onzima were up 26% at 0.944 pence on Monday.
By Hannah Boland; [email protected]; @Hannaheboland
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
ONZ.L